A Phase 3 interventional study of Technosphere® Insulin Inhalation Powder and Usual Care in Diabetes, Type 1 and Diabetes, Type 2, sponsored by Mannkind Corporation. Completed at 176 sites in 8 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-16.
Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 4 that started in 2005, is one of 17 in phase 3, and was the 3rd registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 1989; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,053 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 35 interventional studies. Of the 34 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 3, and was the 2nd registered.
Mannkind Corporation’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 21 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pulmonary Safety in Diabetics with T/I
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For All Subjects:
For Subjects with diabetes mellitus:
For Subjects without abnormalities in glucose control:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technosphere® Insulin Inhalation Powder
Drug: Technosphere® Insulin Inhalation Powder
Usual care
Drug: Usual Care
Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)
Inhalation, 15U/30U
Subjects will receive antidiabetes treatment at the discretion of their physicians
Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care
Change from Baseline to End of Study in FEV1 by MMRM
Time frame: Baseline to Month 24
FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care
FEV1 decrease of ≥ 15% from Baseline value at last measurement
Time frame: Baseline to Month 24
Change From Baseline to Last Measurement in FEV1 for TI vs Usual Care
Change from Baseline to last measurement(Month 24) in FEV1
Time frame: Baseline to Month 24
Change From Baseline to Month 24 in Forced Vital Capacity (FVC) by MMRM
Change from Baseline to Month 24 in FVC by MMRM
Time frame: Baseline to Month 24
Change From Baseline to Month 24 in Total Lung Capacity (TLC) by MMRM
Change from baseline to Month 24 in TLC by MMRM
Time frame: Baseline to Month 24
Change From Baseline to Month 24 in Hemoglobin Corrected DLco by MMRM
Change from baseline to Month 24 in hemoglobin-corrected DLco by MMRM
Time frame: Baseline to Month 24
Forced Vital Capacity (FVC) Decrease of ≥ 15% From Baseline Value at Last Measurement
FVC Decrease of ≥15% from Baseline Value at Last Measurement
Time frame: Baseline to Month 24
Total Lung Capacity (TLC) Decrease of ≥ 15% From Baseline Value at Last Measurement
TLC Decrease of ≥ 15% from Baseline Value at Last Measurement
Time frame: Baseline to Month 24
Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of ≥ 15% From Baseline Value at Last Measurement
Hemoglobin-corrected DLco decrease of ≥ 15% from baseline value at last measurement
Time frame: Baseline to Month 24
Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of >3 ml/Min/mmHg From Baseline Value at Last Measurement
Hemoglobin-corrected DLco decrease of \>3 ml/min/mmHg from baseline value at last measurement
Time frame: Baseline to Month 24
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Last Measurement for TI vs Usual Care
Change from baseline in HbA1c at last measurement
Time frame: Baseline to Month 24
Change in Weight From Baseline at Month 24
Change from baseline in weight at Month 24
Time frame: Baseline to Month 24
First subject enrolled July 25, 2005 Multi-national trial conducted in Canada, Czech Republic, Poland, Russia, Spain, Ukraine, UK, and US
| Milestone | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Started | 938 | 951 | 164 |
| Completed | 475 | 662 | 127 |
| Not completed | 463 | 289 | 37 |
| Withdrew: Adverse event | 104 | 9 | 0 |
| Withdrew: Death | 4 | 3 | 0 |
| Withdrew: Lost to follow-up | 56 | 80 | 5 |
| Withdrew: Physician decision | 15 | 2 | 1 |
| Withdrew: Protocol violation | 34 | 9 | 5 |
| Withdrew: Withdrawal by subject | 218 | 166 | 18 |
| Withdrew: Various | 32 | 20 | 8 |
Change from Baseline to End of Study in FEV1 by MMRM
| liters | Technosphere® Insulin | Usual Care |
|---|---|---|
| Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care | -0.16 ± 0.208 | -0.12 ± 0.211 |
Change from Baseline to last measurement(Month 24) in FEV1
| liters | Technosphere® Insulin | Usual Care |
|---|---|---|
| Change From Baseline to Last Measurement in FEV1 for TI vs Usual Care | -0.128 (-0.144 to -0.113) | -0.092 (-0.107 to -0.077) |
Change from Baseline to Month 24 in FVC by MMRM
| liters | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Change From Baseline to Month 24 in Forced Vital Capacity (FVC) by MMRM | -0.14 ± 0.242 | -0.11 ± 0.262 | -0.09 ± 0.210 |
Change from baseline to Month 24 in TLC by MMRM
| liters | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Change From Baseline to Month 24 in Total Lung Capacity (TLC) by MMRM | -0.05 ± 0.321 | -0.07 ± 0.322 | -0.02 ± 0.297 |
Change from baseline to Month 24 in hemoglobin-corrected DLco by MMRM
| mL/min/mmHg | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Change From Baseline to Month 24 in Hemoglobin Corrected DLco by MMRM | -1.60 ± 2.830 | -1.36 ± 2.862 | -1.33 ± 3.203 |
FVC Decrease of ≥15% from Baseline Value at Last Measurement
| participants | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Forced Vital Capacity (FVC) Decrease of ≥ 15% From Baseline Value at Last Measurement | 23 | 17 | 2 |
TLC Decrease of ≥ 15% from Baseline Value at Last Measurement
| Participants | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Total Lung Capacity (TLC) Decrease of ≥ 15% From Baseline Value at Last Measurement | 7 | 6 | 1 |
Hemoglobin-corrected DLco decrease of ≥ 15% from baseline value at last measurement
| Participants | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of ≥ 15% From Baseline Value at Last Measurement | 105 | 108 | 20 |
Hemoglobin-corrected DLco decrease of \>3 ml/min/mmHg from baseline value at last measurement
| Participants | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Hemoglobin-Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLco) Decrease of >3 ml/Min/mmHg From Baseline Value at Last Measurement | 181 | 181 | 40 |
Change from baseline in HbA1c at last measurement
| percentage | Technosphere® Insulin | Usual Care |
|---|---|---|
| Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Last Measurement for TI vs Usual Care | -0.42 ± 1.410 | -0.49 ± 1.37 |
Change from baseline in weight at Month 24
| kilograms | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| Change in Weight From Baseline at Month 24 | 1.0 ± 6.653 | 1.64 ± 5.066 | 1.19 ± 4.457 |
FEV1 decrease of ≥ 15% from Baseline value at last measurement
| Participants | Technosphere® Insulin | Usual Care |
|---|---|---|
| FEV1 Decrease of ≥ 15% From Baseline Value at Last Measurement for TI vs Usual Care | 42 | 27 |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Technosphere® Insulin | — | 92/923 (10%) | 559/923 (60.6%) |
| Usual Care | — | 91/949 (9.6%) | 472/949 (49.7%) |
| Non-diabetes | — | 5/163 (3.1%) | 47/163 (28.8%) |
| Event | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 9/923 | 10/949 | 0/163 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/923 | 6/949 | 0/163 |
| AppendicitisInfections and infestations | 1/923 | 1/949 | 1/163 |
| CellulitisInfections and infestations | 0/923 | 1/949 | 1/163 |
| Chronic tonsillitisInfections and infestations | 0/923 | 0/949 | 1/163 |
| TenosynovitisMusculoskeletal and connective tissue disorders | 0/923 | 0/949 | 1/163 |
| Benign ovarian tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/923 | 0/949 | 1/163 |
| Cerebrovascular accidentNervous system disorders | 1/923 | 4/949 | 1/163 |
| Coronary artery diseaseCardiac disorders | 5/923 | 3/949 | 0/163 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 5/923 | 4/949 | 0/163 |
| Event | Technosphere® Insulin | Usual Care | Non-diabetes |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 365/923 | 370/949 | 0/163 |
| CoughRespiratory, thoracic and mediastinal disorders | 257/923 | 42/949 | 5/163 |
| Upper respiratory tract infectionInfections and infestations | 119/923 | 143/949 | 35/163 |
| NasopharyngitisInfections and infestations | 67/923 | 69/949 | 14/163 |
Safety population, excluding subjects who were not dosed with study medication (17 diabetics randomized but not dosed, 1 non-diabetic elected not to participate)
| Age, Continuous(years) | Technosphere® Insulin | Usual Care | Non-diabetes | Total |
|---|---|---|---|---|
| Mean | 50.8 ± 11.55 | 50.4 ± 11.62 | 38.2 ± 12.59 | 49.6 ± 12.15 |
| Sex: Female, Male(Participants) | Technosphere® Insulin | Usual Care | Non-diabetes | Total |
|---|---|---|---|---|
| Female | 366 | 371 | 92 | 829 |
| Male | 557 | 578 | 71 | 1206 |
| Body mass index(kilograms per meter squared) | Technosphere® Insulin | Usual Care | Non-diabetes | Total |
|---|---|---|---|---|
| Mean | 29.87 ± 5.366 | 29.76 ± 5.035 | 25.27 ± 4.494 | 29.5 ± 5.29 |
| HbA1c(percentage) | Technosphere® Insulin | Usual Care | Non-diabetes | Total |
|---|---|---|---|---|
| Mean | 8.7 ± 1.39 | 8.7 ± 1.38 | 0 ± 0 | 8.4 ± 1.61 |
| Weight(kilograms) | Technosphere® Insulin | Usual Care | Non-diabetes | Total |
|---|---|---|---|---|
| Mean | 87.69 ± 18.628 | 87.53 ± 17.638 | 74.35 ± 16.204 | 86.6 ± 18.33 |
Showing the first 100 of 176 sites across 8 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2005, a primary completion of Sep 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 6 years 1 month after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human